Immunome
Yahoo Finance • 10 days ago
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
Jack Higgins, Chief Scientific Officer of Immunome(NASDAQ:IMNM), reported the sale of 9,438 shares of common stock in an open-market transaction on April 2, 2026, as disclosed in the SEC Form 4 filing. Transaction summary Metric Value Sh... Full story
Yahoo Finance • 24 days ago
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
On February 17, 2026, ENAVATE Sciences GP, LLC disclosed a buy of 157,800 shares of Zenas BioPharma(NASDAQ:ZBIO), an estimated $5.19 million trade based on quarterly average pricing. ENAVATE Sciences added 157,800 shares of Zenas BioPharm... Full story
Yahoo Finance • last month
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story
Yahoo Finance • 2 months ago
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics(NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissio... Full story
Yahoo Finance • 2 months ago
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome(NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, Redmile Gro... Full story
Yahoo Finance • 2 months ago
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Feb... Full story
Yahoo Finance • 2 months ago
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
Redmile Group reported a purchase of 16,317 shares of Krystal Biotech(NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. What happened According to... Full story
Yahoo Finance • 2 months ago
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation(NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing. What happene... Full story
Yahoo Finance • 2 months ago
Shopify upgraded, Coinbase downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: TD Cowen upgraded Shopify (SHOP) to Bu... Full story
Yahoo Finance • 4 months ago
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story
Yahoo Finance • 4 months ago
Immunome prices $400M stock offering at $21.50 a share
Immunome (IMNM [https://seekingalpha.com/symbol/IMNM]) has priced a public offering [https://seekingalpha.com/pr/20342088-immunome-announces-pricing-of-public-offering-of-common-stock] of 18.63 million shares at $21.50 per share. The compa... Full story
Yahoo Finance • 4 months ago
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways... Full story
Yahoo Finance • 4 months ago
Stocks Fall Ahead of US November Payroll Report
The S&P 500 Index ($SPX) (SPY) on Monday closed down by -0.16%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down by -0.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down by -0.51%. December E-mini S&P futures (ESZ25) fell -0... Full story
Yahoo Finance • 4 months ago
Sector Update: Health Care Stocks Rise in Afternoon Trading
Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the State Stre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
Stock Market Today: Russell 2000, Nasdaq Decline After Strong Start to Trading Week
This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Dec. 15, 2025. You can... Full story
Yahoo Finance • 4 months ago
Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more
Check out the companies making the biggest moves midday: KLA Corp. — The semiconductor equipment maker jumped 4%, nearing a 52-week high, after Jefferies raised its 12-month price target to $1,500 from $1,200, saying "AI continues to drive... Full story
Yahoo Finance • 4 months ago
Stocks Climb in Anticipation of Fed-Friendly US Economic News
The S&P 500 Index ($SPX) (SPY) today is up by +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.27%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.50%. December E-mini S&P futures (ESZ25) are up +0.40%, and December E... Full story
Yahoo Finance • 4 months ago
Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA
Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug. Continue Reading... Full story
Yahoo Finance • 5 months ago
Immunome GAAP EPS of -$0.65
* Immunome press release [https://seekingalpha.com/pr/20297808-immunome-reports-third-quarter-2025-financial-results-and-provides-business-update] (IMNM [https://seekingalpha.com/symbol/IMNM]): Q3 GAAP EPS of -$0.65. * As of September... Full story
Yahoo Finance • 6 months ago
First Week of December 19th Options Trading For Zscaler (ZS)
Investors in Zscaler Inc (Symbol: ZS) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZS options chain for the new December 19th contr... Full story
